Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook
Tweet Send to a FriendGet Alerts ENDP Hot Sheet
Price: $33.73 -0.91%
Revenue Growth %: +2.6%
Financial Fact:
Net pharmaceutical product sales: 535.74M
Today's EPS Names:
DSX, REDF, REX, More
Revenue Growth %: +2.6%
Financial Fact:
Net pharmaceutical product sales: 535.74M
Today's EPS Names:
DSX, REDF, REX, More
Trade ENDP Now!
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Lowes Cos. (LOW) Misses Q1 EPS by 2c; Reaffirms FY13 Outlook
- Dick's Sporting Goods, Inc. (DKS) Reports In-Line Q1 EPS; Guides Q2 EPS, Comps
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
